Table 2 Clinical data
Presence of loculations on CT scan, n (%) | 44 (78.6) |
Number of chest tubes placed | |
1 chest tube placed, n (%) | 53 (94.6) |
2 chest tubes placed, n (%) | 3 (5.4) |
Size of chest tubes placed | |
32 French, n (%) | 3 (5.1) |
12 French, n (%) | 7 (12.5) |
10 French, n (%) | 39 (69.6) |
8 French, n (%) | 10 (17.8) |
Purulent pleural fluid, n (%) | 17 (30.4) |
Positive pleural fluid culture, n (%) | 26 (46.4) |
Organisms found on pleural fluid culture | |
Streptococcus milleri | 8 (30.8) |
Klebsiella pneumoniae | 5 (19.2) |
Staphylococcus aureus, methicillin sensitive | 5 (19.2) |
Staphylococcus aureus, methicillin resistant | 4 (15.4) |
Escherichia coli | 3 (11.5) |
Streptococcus pneumoniae | 2 (7.7) |
Enterobacter aerogenes | 1 (3.8) |
Enterococcus faecium | 1 (3.8) |
Gemella sp | 1 (3.8) |
Median pleural fluid pH (IQR) | 7.08 (6.87–7.18) |
Median pleural fluid lactate dehydrogenase (IQR), IU/L | 4456.5 (1975.8–12,762.5) |
Median peripheral leukocyte count (IQR), × 109/L | 15.9 (12.6–20.5) |
Median ESR (IQR), mm/h | 83.5 (57.5–101.3) |
Median CRP (IQR), mg/L | 8.25 (4.8–16.6) |
Antibiotics, n (%)a | |
Vancomycin | 37 (66.1) |
Piperacillin–tazobactam | 35 (62.5) |
Ceftaroline | 17 (30.4) |
Meropenem | 15 (26.8) |
Metronidazole | 9 (16.1) |
Levofloxacin | 9 (16.1) |
Ceftriaxone | 8 (14.3) |
Azithromycin | 7 (12.5) |
Ampicillin–sulbactam | 7 (12.5) |
Tigecycline | 7 (12.5) |
Clindamycin | 4 (7.1) |
Doxycycline | 3 (5.4) |
Linezolid | 3 (5.4) |
Aztreonam | 2 (3.6) |
Daptomycin | 1 (1.8) |
Penicillin | 1 (1.8) |
Polymixin B | 1 (1.8) |
Number of intrapleural administrations of alteplase/dornase alfa, n (%) | |
One | 5 (8.9) |
Two | 6 (10.7) |
Three | 40 (71.4) |
Four | 1 (1.8) |
Five | 1 (1.8) |
Six | 3 (5.4) |
Patients who received the first dose of intrapleural treatment in under 24 h after chest tube insertion, n (%) | 37 (66.1) |
Median days from chest tube insertion to first dose of intrapleural treatment (IQR) | 1 (0–2) |